PHYSIOTHERAPIST-LED CARE FOR MUSCULOSKELETAL CONDITIONS IN THE EMERGENCY DEPARTMENT
With
Associate Professor Gustavo Machado
University of Sydney &
NHMRC Principal Research Fellow,
Institute for Musculoskeletal Health, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | November 2026
Associate Professor Gustavo Machado is a physiotherapist and health services researcher at the University of Sydney and the Institute for Musculoskeletal Health, Sydney Local Health District. He holds an NHMRC Investigator Fellowship (EL2) and a University of Sydney Robinson Fellowship.
With over 15 years of research experience, he leads a program focused on transforming musculoskeletal and emergency care through evidence-based practice. His research involves large-scale clinical trials evaluating treatments for musculoskeletal pain, strategies to reduce low-value care, and innovative models of emergency, hospital and virtual care. His work aims to improve patient outcomes, healthcare efficiency and health system sustainability.
Associate Professor Machado has published over 150 peer-reviewed papers in leading journals, including The Lancet, The BMJ, The Lancet Rheumatology and JAMA Health Forum, attracting more than 6,500 citations. He ranks among the world’s top 2% of scientists (Stanford/Elsevier), and his research has informed over 100 policy documents across 17 countries.
He has secured $29 million in competitive research funding as a Chief Investigator and received 30 research and impact awards, including the Research Australia Award, ANZMUSC Trial of the Year and NSW Health Secretary’s Award.
Funding for Associate Professor Machado’s research has included National Health and Medical Research Council (NHMRC), Medical Research Futures Fund, HCF Australia Research Foundation and Ramsay Hospital Research Foundation.
His collaborations include NSW Ambulance, NSW Agency for Clinical Innovation, Australian Physiotherapy Association, Australasian College for Emergency Medicine and the Australian & New Zealand College of Emergency Nursing.
He contributes to national research and health policy committees, including the NHMRC, Australasian College for Emergency Medicine and ANZMUSC. He is a Fellow of the International Society for Quality in Health Care and a member of the Royal Society of NSW.
Source: Supplied and adapted
https://orcid.org/0000-0002-8544-0448
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Dr Meghan McIlwain
DR MEGHAN MCILWAIN, CLINICAL RESEARCH MANAGER
PRESIDENT, THE NEW ZEALAND ASSOCIATION OF CLINICAL RESEARCH,
AUCKLAND, NEW ZEALAND -
Dr Ryan O’Hare Doig
NEIL SACHSE CENTRE FOR SPINAL CORD RESEARCH (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA
